Viridian Therapeutics, Inc.DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30260% above fair value
$29.96−1.48 (-4.71%)
Close on Nov 20, 2026Market cap $3.39BP/E –Yield –
Viridian Therapeutics, Inc.DE operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Viridian Therapeutics, Inc.DE's operating income for the twelve months ending Jun 30, 2026 was -$405.20M. For fiscal 2025 it was -$363.40M. The highest annual figure on record is -$197.00K in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$363.40M | – |
| FY2024 | Dec 31, 2024 | -$299.04M | – |
| FY2023 | Dec 31, 2023 | -$254.45M | – |
| FY2022 | Dec 31, 2022 | -$134.30M | – |
| FY2021 | Dec 31, 2021 | -$79.73M | – |
| FY2020 | Dec 31, 2020 | -$110.38M | – |
| FY2019 | Dec 31, 2019 | -$41.98M | – |
| FY2018 | Dec 31, 2018 | -$33.08M | – |
| FY2017 | Dec 31, 2017 | -$26.53M | – |
| FY2016 | Dec 31, 2016 | -$16.99M | – |
| FY2015 | Dec 31, 2015 | -$11.19M | – |
| FY2014 | Dec 31, 2014 | -$6.87M | – |
| FY2013 | Dec 31, 2013 | -$197.00K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$126.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$116.17M | – |
| Q4 FY2025 | Dec 31, 2025 | -$122.75M | – |
| Q3 FY2025 | Sep 30, 2025 | -$40.01M | – |
| Q2 FY2025 | Jun 30, 2025 | -$106.77M | – |
| Q1 FY2025 | Mar 31, 2025 | -$93.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$87.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$83.48M | – |
| Q2 FY2024 | Jun 30, 2024 | -$72.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$55.90M | – |
| Q4 FY2023 | Dec 31, 2023 | -$71.48M | – |
| Q3 FY2023 | Sep 30, 2023 | -$51.22M | – |
| Q2 FY2023 | Jun 30, 2023 | -$59.28M | – |
| Q1 FY2023 | Mar 31, 2023 | -$72.47M | – |
| Q4 FY2022 | Dec 31, 2022 | -$49.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.79M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.56M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.89M | – |
| Q4 FY2021 | Dec 31, 2021 | -$29.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.13M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.52M | – |
| Q4 FY2020 | Dec 31, 2020 | -$90.60M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.41M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.07M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.23M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.94M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.74M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.45M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.15M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.86M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.62M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.35M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.89M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.35M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.94M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.91M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.08M | – |
See a number that looks wrong?